GlaxoSmithKline S.A.E (EGX:BIOC)

Egypt · Delayed Price · Currency is EGP

71.02

-2.17 (-2.96%)

At close: Jun 24, 2026

90.20% (1Y)

Market Cap	5.93B +80.4%
Revenue (ttm)	3.73B +24.7%
Net Income	213.23M +22.6%
EPS	2.55 +22.6%
Shares Out	83.51M
PE Ratio	27.82
Forward PE	n/a
Dividend	1.00 (1.41%)
Ex-Dividend Date	Jan 12, 2026

Volume	27,425
Open	73.19
Previous Close	73.19
Day's Range	71.00 - 73.44
52-Week Range	37.11 - 81.50
Beta	0.79
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About GlaxoSmithKline S.A.E

GlaxoSmithKline S.A.E engages in production of pharmaceutical chemicals. The company is involved in manufacture of general and specialty medicines, and vaccines. GlaxoSmithKline S.A.E was founded in 1981 and is based in New Cairo, Egypt. GlaxoSmithKline S.A.E operates as a subsidiary of Glaxo Group Limited. [Read more]

Industry Pharmaceutical Preparations

Founded 1981

Employees 800

Stock Exchange Egyptian Stock Exchange

Ticker Symbol BIOC

Full Company Profile

Financial Performance

In 2025, GlaxoSmithKline S.A.E's revenue was 3.73 billion, an increase of 24.73% compared to the previous year's 2.99 billion. Earnings were 213.23 million, an increase of 22.56%.

Financial Statements